Under the Paperwork Reduction Act of 1995, no persons are req a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10597817
Filing Date		2006-08-08
First Named Inventor Hu		
Art Unit		1731
Examiner Name		
Attorney Docket Number		101330-1P US

		· ·			U.S.I	PATENTS			Remove		
Examiner Initial*	miner Cite Patent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear								
	1	5288725		1994-02	1-22	Witherup et al.					
If you wisl	h to a	i dd additional U.S. Pater	t citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>					nt Passas	Columns,Lines where it Passages or Relevant Appear		
	1										
If you wis	h to a	dd additional U.S. Publi		,				d button	Add		
	_			FOREIG	SN PAT	ENT DOCUM	ENTS				_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cited Document	or v	vhere Rel	or Relevant	т.
	1	1221439	EP			2002-07-10	Kaken Pharmaceut Co., Ltd.	ical			
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Initials* No (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тв					

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10597817
Filing Date		2006-08-08
First Named Inventor Hu		
Art Unit		1731
Examiner Name		
Attornou Docket Numb	or	101330-1P US

Date Considered

Hexarbydropyroio(3,2-g/Cuiriolite Alkaloid Martinelline,** Chiem. Commun., pages 2362,2963,2001  HADDEN, M. et al., "Synthesis and Readivity of Hexarbydropyrologuandines," Tetrahedron, Vol. 57, pages 5615-5624, 201  LEACH, C. et al., "Reventible bribblors of the Cleans (H-MK+)-ATPese. 2. 1-Arytopyrolo(3,2-c)quinolines: Effect of the 4-Substituent," J. Med. Chem., Vol. 35, pages 1945-1952, 1992  M. D. et al., "First Total Synthesis of Martinelle Acid, a Naturally Occurring Bradykinn Receptor Artagonist," Organic Letters, Vol. 3, No. 14, pages 2189-2191, 2001  NYERGES, M., "Construction of Pyrriob(3,2-c)Quinolines - Recent Advances in the Synthesis of the Martinelline Alkaloids," Heterocycles, Vol. 53, No. 7, pages 1985-1987, 2004  WITHERUP, K. et al., "Martinelline and Martinellic Acid, Novel G-Proten Linked Receptor Antagonists from the Tropical Plant Martinellin (subsenses (Byronacces)," J. Am. Chem. Soc., Vol. 117, pages 6652-6855, 1995	If you wish to	add additional non-patent literature document citation information please click the Add button Add  FXAMINER SIGNATURE	
Hexarbydropyroio(3,2-g/Cuiriolite Alkaloid Martinelline,* Chem. Commun., pages 2362,2963, 2001      HADDEN, M. et al., "Synthesis and Readoutly of Hexarbydropyrologuandines," Tetrahedron, Vol. 57, pages 5615-5624, 2011      LEACH, C. et al., "Reventible Inhibitors of the Gastro (HHK+)-ATPase. 2. 1-Arytopyrolo(3,2-c)gunolines: Effect of the 4-Substituent," J. Med. Chem., Vol. 35, pages 1945-1952, 1992      MA, D. et al., "First Total Synthesis of Martinellic Acid, a Naturally Occurring Bradylunn Receptor Antagonist," Organic Letters, Vol. 3, No. 14, pages 2189-2191, 2001      NYERGES, M., "Construction of Pyrrob(3,2-g/Cuircines - Recent Advances in the Synthesis of the Martinelline."		Tropical Plant Martinella iquitosensis (Bignoniaceae)," J. Am. Chem. Soc., Vol. 117, pages 6682-6685, 1995	
Hoxarbydropyroio(3.2-c)Cusinolise Alkaleid Martineline,** Chiem. Commun., pages 2362;2963, 2001      HADDEN, M. et al., "Synthesis and Readivity of Hexarbydropyrologuandines," Tetrahedron, Vol. 57, pages 5615-5624, 2001      LEACH, C. et al., "Reversible Inhibitors of the Gastro (HHK*+ATPase. 2. 1-Aryteyrolo(3.2-c)cunnolines: Effect of the 4-Substituent," J. Med. Chem., Vol. 35, pages 1945-1952, 1962      MA, D. et al., "Fert Total Synthesis of Martinelle Acut, a Naturally Cocurring Braslykinn Receptor Antagonist," Organic	5		
Hexarbydropyroio(3.2-g/Duleolite Alkalaid Martinelline,* Chiem. Commun., pages 2382;2993, 2001      HADDEN, M. et al., "Synthesis and Readilvity of Hexarbydropyroloquinolines,* Tetrahedron, Vol. 57, pages 5615-5624, 2001      LEACH, C. et al., "Reversible inhibitors of the Gastro (H-MY-)-ATPase. 2. 1-Arybyrolo(3.2-c)quinolines. Effect of the	4		
Hexatrydropyrolo(3,2-gDuinoline Alkaloid Martinelline,* Chem. Commun., pages 2362-2363, 2001     HADDEN, M. et al., "Synthesia and Readurity of Hexatrydropyrologunolines,* Tetrahedron, Vol. 57, pages 5615-5624,	3		
	2		
	1	BATEY, R. et al., "Multi-Component Coupling Reactions: Synthesis of a Guanidine Containing Analog of the Hexahydropyrrolo(3,2-c)Quinoline Alkabid Martinelline," Chem. Commun., pages 2382-2363, 2001	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at wew USPTO.GOV or MPEP 90.04. Esters dotte that issued the document, by the love labor code (WIPO Standard ST.3). "For Just pursees peter for but counters, the included on the year of the region of the Emportor many precised he serial results where of the patent document." A fixed of document by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. Speciated is to place a check mark here if English Barquages theresisted in a statistic.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10597817		
	Filing Date		2006-08-08		
	First Named Inventor	Hu			
	Art Unit		1731		
Examiner Name Attorney Docket Number					
		er	101330-1P US		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c).

1	See	attached	certification	statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

V Non

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Jianzhong SHEN, Reg.#48076/	Date (YYYY-MM-DD)	2006-11-07
Name/Print	Jianzhong Shen	Registration Number	48.076

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.